# OnCo record advanced-small-bowel-adenocarcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/advanced-small-bowel-adenocarcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "advanced-small-bowel-adenocarcinoma" ;
  schema:name "Advanced and metastatic small bowel adenocarcinoma"@en ;
  schema:alternateName "Metastatic small bowel adenocarcinoma"@en, "Stage IV SBA"@en, "Unresectable small intestine adenocarcinoma"@en, "Recurrent small bowel adenocarcinoma"@en ;
  schema:description "Advanced small bowel adenocarcinoma is cancer of the small intestine that has spread to the liver, peritoneum or elsewhere, treated with the chemotherapy used for bowel cancer, oxaliplatin with a fluoropyrimidine, then taxanes or irinotecan. The exception is the sizeable minority with mismatch-repair-deficient tumours, for whom the immunotherapy pembrolizumab works far better than chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/advanced-small-bowel-adenocarcinoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Small_intestine_cancer> ;
  schema:citation <https://doi.org/10.1200/JCO.2008.19.7145>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1490>, <https://en.wikipedia.org/wiki/Small_intestine_cancer> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/localised-small-bowel-adenocarcinoma/>, <https://onco.cc/cancers/small-bowel/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/hipec/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/peritoneal-metastasis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-overman-capox-small-bowel-adenocarcinoma-jco-2009/>, <https://onco.cc/key-papers/paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021/> ;
  onco:pipeline <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/signatera/> ;
  onco:standardOfCare <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/terms/msi/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/terms/peritoneal-metastasis/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/terms/tumour-agnostic/> .